Adverse events in relation to GLP-1R agonists for the treatment of obesity are mainly gastrointestinal side effects, including nausea, diarrhoea, vomiting and constipation, which is consistent with observations in type 2 diabetes, and rates of discontinuation due to adverse events are generally higher with GLP-1R agonists treatment compared with placebo [26, 30,31,32,33,34,35,36,37,38,39]
Log in to keep reading or access research tools and resources.
The medication handles the caloric deficit
Cigna confirmed to me that the roughly 17 percentage point gap remained for 2020, but the company did not provide any specific figures
If you have questions about your Lantus dosage for type 2 diabetes, talk with your doctor or pharmacist